Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial


Ahren B., Masmiquel L., Kumar H., Sargin M. , Karsbol J. D. , Jacobsen S. H. , et al.

LANCET DIABETES & ENDOCRINOLOGY, cilt.5, ss.341-354, 2017 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 5 Konu: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/s2213-8587(17)30092-x
  • Dergi Adı: LANCET DIABETES & ENDOCRINOLOGY
  • Sayfa Sayısı: ss.341-354

Özet

Background Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for once-weekly subcutaneous administration, in development for treatment of type 2 diabetes. We assessed the efficacy and safety of semaglutide versus the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both.